Dose News Briefs

Microdosing GLP-1s Like Wegovy, Zepbound May Still Lead to Weight Loss. Research shows that microdosing GLP-1 medications may still lead to weight loss. Tatsiana Volkava · Moment/Getty Recent research suggests that people may still lose weight while staying on the lowest starting doses of GLP-1 medications, such as Wegovy or Zepbound, for longer periods. After one year, people taking sustained low dose tirzepatide lost about 5.5% of their body weight, while those taking sustained low dose semaglutide lost about 2.2%. Lower doses were associated with more modest weight loss than higher doses, but sustained low dose semaglutide was also associated.